The clinically most relevant receptors are the cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) and programmed cell death protein 1 (PD-1) as they can be blocked by targeted therapies which are currently used for various malignant tumor types, including lung cancer. This evidence concerns the gene CTLA4 and lung carcinoma.